Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is a phase III trial to explore the efficacy and safety of vinorelbine plus capecitabine (NX) and docetaxel plus capecitabine (TX) as first line treatment followed by capecitabine alone till Progressive Disease(PD). We plan to enroll 200 pts for limited budget and the non-inferior trend of the two curves is anticipated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer

NCT01635465

Anthracycline-pretreated Metastatic Breast Cancer

UNKNOWN

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

NCT03887130

Breast Cancer

COMPLETED PHASE2

Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)

NCT00629148

Breast Cancer Metastasis, Neoplasm

COMPLETED PHASE2

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

NCT04159142

Triple Negative Breast Cancer Nab-paclitaxel

RECRUITING PHASE2

Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy

NCT03821454

Breast Cancer

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We designed the randomized non-inferiority study. Main Inclusion\& exclusion Criteria include: 1) Histologically or cytologically confirmed breast cancer with unresectable locally advanced and/or metastatic disease; 2) Untreated patients with unresectable locally advanced and/or metastatic disease; 3) with at least 1 lesion measurable by radiological method(RECIST criteria); 4) Karnofsky Performance Status(KPS)≥70; 5) normal Adequate hepatic, renal, and bone marrow function; 6) Life expectancy of at least 12 weeks; 7) No previous chemotherapy for metastatic breast cancer. Primary endpoint is Progression free survival(PFS), second endpoint are safety profiles (National Cancer Institute-Common Toxicity Criteria 3.0, NCI-CTC 3.0), overall survival and response rate. During Primary study treatment, Arm A: Capecitabine: 1,000 mg/m2 per ora(PO) twice daily (day 1-14), Vinorelbine 25 mg/m2 intravenous(IV) over 3 hours on day 1 and 8, every 3 weeks, 21 days as one cycle and 6-8 cycles are required; Arm B: Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6-8 cycles are required. Patients who are responding (complete or partial), or whose disease is stable followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Invasive Ductal, Breast

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

Vinorelbine plus Capecitabine

Group Type OTHER

Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine

Intervention Type DRUG

Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required

Arm B

Docetaxel plus Capecitabine

Group Type OTHER

Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine

Intervention Type DRUG

Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.

Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine

Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required

Intervention Type DRUG

Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine

Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.

Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written and signed informed consent prior to beginning specific protocol procedures.
* Pathologically confirmed breast cancer and documented metastatic or locally advanced disease.

Measurable disease (RECIST criteria) - with at least 1 lesion measurable by radiological method

* KPS\>=70
* Adjuvant and/or Neoadjuvant chemotherapy, including an anthracycline was permitted
* Hormone therapy for early-stage or metastatic breast cancer was permitted if hormonal receptor positive.
* Treatment with Herceptin for early-stage or metastatic breast cancer is permitted if HER2 positive
* Patients had to have concluded prior radiation therapy at least 14 days before enrollment.
* Laboratory requirements:

* Hematology Absolute neutrophil count\>=1,500 /μl; Platelets\>=100,000 /μl; Hemoglobin\>=10 g/dl
* Liver function Total bilirubin\<=2 times ULN ASAT (SGOT) and ALAT (SGPT)\<=2.5 times UNL without liver metastasis or \<=5.0 times if liver metastasis Glucose\<=200 mg/dL
* Renal function Serum creatinine\<=140 mol/l
* Life expectancy of at least 12 weeks
* Patients must be accessible for treatment and follow-up.
* Patients should have recovered from the acute reversible effects of prior treatment. This generally means at least 3 weeks should have elapsed since prior chemotherapy, adjuvant or Neoadjuvant treatment. and at least 4 weeks since prior (radical) radiotherapy or major surgery

Exclusion Criteria

* Women who are pregnant or breast feeding
* History of brain and/or leptomeningeal metastases
* Previous chemotherapy for metastatic breast cancer
* Past or current history of malignant neoplasm other than breast carcinoma, except for curatively treated non melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
* Pre-existing neuropathy grade 1 according to the NCIC-CTC 3.0
* Psychiatric disorders or other conditions which would prevent pt. compliance
* Other serious illness or medical condition:

* Congestive heart failure, or unstable angina pectoris, previous history of myocardial infarction within 6 month prior to study entry, uncontrolled hypertension as determined by the Investigator or high risk uncontrolled, arrhythmia.
* History of significant neurological or psychiatric disorders including psychotic disorders, dementia of seizures that would prohibit the understanding and giving of informed consent.
* Active uncontrolled infection.
* Unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of Corticosteroids.
* Inability to take and/or absorb oral medicine
* Prior treatment with an docetaxel and/or capecitabine and/or vinorbine
* Concurrent treatment with other experimental drugs, or participation in another clinical trial with any investigational drug within 30 days prior to study entry

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No